Regulation 221
1. A medicinal product that contains aloxiprin, aspirin or paracetamol (or, where appropriate, any combination of those substances) and that is in the form specified in column 1 of the following table must be presented for sale in a separate and individual package containing not more than the amount of the product specified in the corresponding entry in column 2—U.K.
| Column 1 | Column 2 |
|---|---|
Effervescent tablets— (a) that do not contain aspirin, or (b) that do not contain more than 325 milligrams of aspirin per tablet. | 30 tablets |
Effervescent tablets— (a) that contain more than 325 milligrams of aspirin per tablet, but (b) that do not contain more than 500 milligrams per tablet. | 20 tablets |
Non-effervescent tablets— (a) that are enteric-coated, (b) that contain aspirin only, and (c) that do not contain more than 75 milligrams per tablet. | 28 tablets |
| Other non-effervescent tablets | 16 tablets |
| Powder or granules | 10 sachets |
| Capsules | 16 capsules |
| Liquid preparations of paracetamol intended for persons aged 12 years and over | 160 millilitres |
| Liquid preparations of paracetamol intended for persons aged less than 12 years | Individual unit doses of not more than 5 millilitres each, to a maximum of 20 unit doses |
2. A medicinal product that contains ibuprofen and that is in the form specified in column 1 of the following table must be presented for sale in a separate and individual package containing not more than the amount of the product specified in the corresponding entry in column 2—U.K.
| Form of product | Maximum amount |
|---|---|
| Tablets | 16 tablets |
| Capsules | 16 capsules |
| Powder or granules | 12 sachets |
| Liquid preparations of ibuprofen | Individual unit doses of not more than 5 millilitres each, to a maximum of 20 unit doses |